Medios AG Appoints Stefan Bauerreis as New CFO Amid European Expansion

A seasoned finance veteran steps into Medios AG's top role. Can Bauerreis' strategic vision propel the company's next phase of specialty pharmaceutical expansion?

, and Administrator

2026 March 27 . 3:02 AM

1 min read

The image shows a graph depicting the increased BAA issuance across industry groups. The graph is... — The image shows a graph depicting the increased BAA issuance across industry groups. The graph is accompanied by text that provides further information about the data.

Medios AG Appoints Stefan Bauerreis as New CFO Amid European Expansion

Medios AG, Germany's first listed specialty pharmaceutical company, has named Stefan Bauerreis as its new Chief Financial Officer. His appointment takes effect on April 15, 2026, following the planned departure of current CFO Falk Neukirch. The company, which trades on the Frankfurt Stock Exchange and is part of the SDAX index, continues to expand its presence across Europe.

Stefan Bauerreis brings years of financial leadership to Medios AG. Previously, he served as CFO of Stabilus Group and held senior finance positions at Schaeffler Group. His expertise spans corporate accounting, controlling, financing, and guiding international companies through transformation.

Dr. Yann Samson, Chairman of Medios AG's Supervisory Board, highlighted Bauerreis' operational strengths and strategic vision. Bauerreis himself expressed enthusiasm for the role, stating his commitment to supporting the company's growth in the specialty pharmaceutical sector. Medios AG currently employs 1,003 people across Germany, the Netherlands, Belgium, and Spain. The company specialises in individualised medicine and has a busy schedule for 2026, including financial conferences in Frankfurt and Paris, its Annual General Meeting, and the release of key financial reports.

Bauerreis will officially take over from Falk Neukirch, whose term ends on April 30, 2026. His appointment aligns with Medios AG's goal of reinforcing its financial leadership as it expands further in Europe. The company remains focused on advancing its position in the specialty pharmaceutical market.